A study of REGN3767, an anti-LAG-3 antibody, alone and in combination with cemiplimab (REGN2810), an anti-PD1 antibody, in advanced cancers.

TPS3127Background: Lymphocyte activation gene 3 (LAG-3) is an immune checkpoint receptor with a biological role in T cell regulation. Analysis of immune-cell infiltrates from human tumors show that...